Catalyst
Slingshot members are tracking this event:
Summit’s IND Cleared by FDA Allowing Expansion of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| SMMT |
|
|
||||
Additional Information
• Enrolment of Patients with DMD in the US Expected to Start 3Q 2016
• Utrophin Modulation Offers Differentiated Approach in DMD
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 26, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phaseout Dmd, Ezutromid, Smt C1100, Utrophin Modulator, Duchenne Muscular Dystrophy
